A phase II trial investigates the efficacy and safety of Avelumab treatment together with Domatinostat (NCT04393753, see Table 1) for MCC progressing after anti-PD-1/PD-L1 therapy. Here, PDCD1 is linked to Merkel cell skin cancer.